Výsledky vyhledávání - "Daniel Sehrt"

Akademický článek

Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans

Autor: Johannes Matthaei, Wagner Hugo Bonat, Reinhold Kerb, Mladen Vassilev Tzvetkov, Jakob Strube, Stefanie Brunke, Cordula Sachse-Seeboth, Daniel Sehrt, Ute Hofmann, Jacob von Bornemann Hjelmborg, Matthias Schwab, Jürgen Brockmöller

Publikováno v: Frontiers in Genetics, Vol 11 (2020)

Human CYP3A enzymes (including CYP3A4 and CYP4A5) metabolize about 40% of all drugs and numerous other environmental and endogenous substances. CYP3A activity is highly variable within and between humans. As a consequence, therapy with standard doses

Externí odkaz: https://doaj.org/article/06cfdc1c43bd47929668ebb95020f727

Zobrazit plný text záznamu

Akademický článek

Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters

Autor: Johannes Matthaei, Mladen V. Tzvetkov, Valerie Gal, Cordula Sachse-Seeboth, Daniel Sehrt, Jakob B. Hjelmborg, Ute Hofmann, Matthias Schwab, Reinhold Kerb, Jürgen Brockmöller

Publikováno v: Genome Medicine, Vol 8, Iss 1, Pp 1-12 (2016)

Abstract Background Efflux transporters like MDR1 and MRP2 may modulate the pharmacokinetics of about 50 % of all drugs. It is currently unknown how much of the variation in the activities of important drug membrane transporters like MDR1 or MRP2 is

Externí odkaz: https://doaj.org/article/5077177727214b0b85b2ff38ab65f715

Zobrazit plný text záznamu

Supplementary Figure Legend from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

Autor: Antonio Jimeno, Aik-Choon Tan, Marileila Varella-Garcia, Barbara A. Frederick, Francois Wilhelm, Dara L. Aisner, Sarah M. Takimoto, Daniel Sehrt, Brian W. Vogler, Gregory N. Gan, Justin Eagles-Soukup, Adrian Umpierrez, Phuong Le, J. Jason Morton, David P. Astling, Magdalena J. Glogowska, Daniel W. Bowles, Stephen B. Keysar, Ryan T. Anderson

PDF file - 64K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e8e7717de4950956e210d0d4a5249dc
https://doi.org/10.1158/1535-7163.22497478

Zobrazit plný text záznamu

Data from The Dual Pathway Inhibitor Rigosertib Is Effective in Direct Patient Tumor Xenografts of Head and Neck Squamous Cell Carcinomas

The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in squamous cell carci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36906326f4b2438531275d5ad4819da3
https://doi.org/10.1158/1535-7163.c.6535627.v1

Zobrazit plný text záznamu

Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2

Autor: Reinhold Kerb, Johannes Matthaei, Jacob v. B. Hjelmborg, Matthias Schwab, Daniel Sehrt, Mladen V. Tzvetkov, Ulrich Halekoh, Cordula Sachse-Seeboth, Jürgen Brockmöller, Ute Hofmann, Sören Möller, Jakob Strube

Publikováno v: Clinical Pharmacology & Therapeutics. 100:606-616

Heritability of caffeine pharmacokinetics and cytochrome P450 1A2 (CYP1A2) activity is controversial. Here, we analyzed the pharmacokinetics of caffeine, an in vivo probe drug for CYP1A2 and arylamine N-acetyltransferase 2 (NAT2) activity, in monozyg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b6bbd60c853c1d9c83b59861c93260e1
https://doi.org/10.1002/cpt.444

Zobrazit plný text záznamu

The Circadian PER2 Enhancer Nobiletin Reverses the Deleterious Effects of Midazolam in Myocardial Ischemia and Reperfusion Injury

Autor: Colleen Marie Bartman, Jennifer Gile, Tobias Eckle, Daniel Sehrt, Yoshimasa Oyama

Publikováno v: Current pharmaceutical design. 24(28)

Background: Recently, we identified the circadian rhythm protein Period 2 (PER2) in robust cardioprotection from myocardial ischemia (MI). Based on findings that perioperative MI is the most common major cardiovascular complication and that anestheti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95d03c310dd0022f3587b2450ff4a0ee
https://pubmed.ncbi.nlm.nih.gov/30246635

Zobrazit plný text záznamu

Hedgehog Signaling Alters Reliance on EGF Receptor Signaling and Mediates Anti-EGFR Therapeutic Resistance in Head and Neck Cancer

Publikováno v: Cancer Research. 73:3381-3392

The EGF receptor (EGFR)-directed monoclonal antibody cetuximab is the only targeted therapy approved for the treatment of squamous cell carcinoma of the head and neck (HNSCC) but is only effective in a minority of patients. Epithelial-to-mesenchymal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8185652e9e3d11d0876b4304c46be8e4
https://doi.org/10.1158/0008-5472.can-12-4047

Zobrazit plný text záznamu

A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

Publikováno v: Molecular Oncology. 7:776-790

Targeted therapy development in head and neck squamous cell carcinoma (HNSCC) is challenging given the rarity of activating mutations. Additionally, HNSCC incidence is increasing related to human papillomavirus (HPV). We sought to develop an in vivo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94f6a2e108308f820a193b69aef1e143
https://doi.org/10.1016/j.molonc.2013.03.004

Zobrazit plný text záznamu

Heritability of metoprolol and torsemide pharmacokinetics

Autor: Daniel Sehrt, Matthias Schwab, Mladen V. Tzvetkov, Cordula Sachse-Seeboth, Ute Hofmann, Sören Möller, Ulrich Halekoh, Jacob v. B. Hjelmborg, Jürgen Brockmöller, Johannes Matthaei, Reinhold Kerb

Publikováno v: Matthaei, J, Brockmöller, J, Tzvetkov, M, Sehrt, D, Sachse-Seeboth, C, Hjelmborg, J V B, Möller, S, Halekoh, U, Hofmann, U, Schwab, M & Kerb, R 2015, ' Heritability of metoprolol and torsemide pharmacokinetics ', Clinical Pharmacology and Therapeutics, vol. 98, no. 6, pp. 611-621 . https://doi.org/10.1002/cpt.258

Genetic variation in the pharmacokinetics of metoprolol and torsemide due to polymorphisms in CYP2D6, CYP2C9, and OATP1B1 has been extensively studied. However, it is still unknown how much of the variation in pharmacokinetics of these two clinically

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab3eee0207e12981e67f226bbf1b3c87
https://portal.findresearcher.sdu.dk/da/publications/09c139b8-a310-4344-b293-642eaed23ec0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání